Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1002/clc.18

http://scihub22266oqcxt.onion/10.1002/clc.18
suck pdf from google scholar
17847041!6653254!17847041
unlimited free pdf from europmc17847041    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid17847041      Clin+Cardiol 2007 ; 30 (11): 546-51
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Hyponatremia and vasopressin antagonism in congestive heart failure #MMPMID17847041
  • Kumar S; Rubin S; Mather PJ; Whellan DJ
  • Clin Cardiol 2007[Nov]; 30 (11): 546-51 PMID17847041show ga
  • In a national heart failure registry, hyponatremia (serum sodium < 130 mEq/L) was initially reported in 5% of patients and considered a risk factor for increased morbidity and mortality. In a chronic heart failure study, serum sodium level on admission predicted an increased length of stay for cardiovascular causes and increased mortality within 60 days of discharge. Hyponatremia in patients with congestive heart failure (CHF) is associated with a higher mortality rate. Also, by monitoring and increasing serum sodium levels during hospitalization for CHF, patient outcomes may improve. This review describes the pathophysiology of hyponatremia in relation to CHF, including the mechanism of action of vasopressin receptors in the kidney, and assesses the preclinical and clinical trials of vasopressin receptor antagonists--agents recently developed to treat hyponatremia. In hospitalized patients with CHF, hyponatremia plays a major role in poor outcomes. Vasopressin receptor antagonists have been shown to be safe and effective in clinical trials in patients with hyponatremia.
  • |Arginine Vasopressin/metabolism[MESH]
  • |Azepines/pharmacology[MESH]
  • |Benzamides/pharmacology[MESH]
  • |Benzazepines/pharmacology[MESH]
  • |Chronic Disease[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Diuretics/pharmacology[MESH]
  • |Heart Failure/*complications/*diagnosis[MESH]
  • |Humans[MESH]
  • |Hyponatremia/*complications/*diagnosis[MESH]
  • |Models, Biological[MESH]
  • |Pyrroles[MESH]
  • |Registries[MESH]
  • |Renin-Angiotensin System[MESH]
  • |Sodium/blood[MESH]
  • |Tolvaptan[MESH]
  • |Treatment Outcome[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box